SCHEMBL17948895

SCHEMBL17948895

Cn1cc(S(=O)(=O)C(F)(F)C2CCN(C(=O)Nc3ccc(F)nc3)CC2)c(C(F)F)n1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.37
TRPV1 Q8NER1 3/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NTRK1 P04629 1/20 0.34
KCNH2 Q12809 1/20 0.34
NTRK3 Q16288 1/20 0.34
NTRK2 Q16620 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
CNR2 P34972 1/20 0.34
IRAK4 Q9NWZ3 2/20 0.33
CSNK1E P49674 1/20 0.33
SLC6A3 Q01959 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29529681 1.00 EPHX2 (0.37) EPHX2TRPV1KMT2ALMNANPSR1
SCHEMBL17948963 0.93 EPHX2 (0.37) EPHX2TRPV1KMT2ANTRK1KCNH2
SCHEMBL17949391 0.93 EPHX2 (0.37) EPHX2TRPV1KMT2ANTRK1KCNH2
SCHEMBL18011652 0.93 EPHX2 (0.37) EPHX2TRPV1KMT2ANTRK1KCNH2
SCHEMBL17949453 0.92 CSNK1E (0.35) EPHX2TRPV1KMT2ALMNANPSR1
SCHEMBL29530191 0.92 CSNK1E (0.35) EPHX2TRPV1KMT2ALMNANPSR1
SCHEMBL29529739 0.92 TRPV1 (0.38) EPHX2TRPV1KMT2ALMNANPSR1
SCHEMBL17948891 0.92 TRPV1 (0.38) EPHX2TRPV1KMT2ALMNANPSR1
SCHEMBL17949004 0.89 PANK3 (0.38) EPHX2TRPV1LMNANPSR1NTRK1
SCHEMBL17949060 0.87 LMNA (0.36) EPHX2TRPV1LMNANPSR1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4234017-A2 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MyoKardia, Inc. (US) 2023-08-30 EP disclosed
EP-3247707-B1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MYOKARDIA INC (US) 2023-05-31 EP disclosed
EP-3247707-B1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) MYOKARDIA INC (US) 2023-05-31 EP disclosed
US-20220117955-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MyoKardia, Inc. 2022-04-21 US disclosed
US-11123337-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2021-09-21 US disclosed
US-20200345716-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2020-11-05 US disclosed
US-10758525-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2020-09-01 US disclosed
US-10758525-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2020-09-01 US disclosed
US-20200113887-A9 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MyoKardia, Inc. 2020-04-16 US disclosed
US-20200113887-A9 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MyoKardia, Inc. 2020-04-16 US disclosed
US-20190269669-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MYOKARDIA INC (US) 2019-09-05 US disclosed
US-20190269669-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MYOKARDIA INC (US) 2019-09-05 US disclosed
US-9925177-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2018-03-27 US disclosed
US-9925177-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2018-03-27 US disclosed
US-9925177-B2 4-methylsulfonyl-substituted piperidine urea compounds MyoKardia, Inc. (US) 2018-03-27 US disclosed
US-20160243100-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2016-08-25 US disclosed
US-20160243100-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2016-08-25 US disclosed
US-20160243100-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds MyoKardia, Inc. 2016-08-25 US disclosed
WO-2016118774-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) MyoKardia, Inc. (US) 2016-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200113887-A9 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885
US-20220117955-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885
US-10758525-B2 4-methylsulfonyl-substituted piperidine urea compounds TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885
US-20190269669-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885
US-20200345716-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885
US-20160243100-A1 4-Methylsulfonyl-Substituted Piperidine Urea Compounds TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885
US-11123337-B2 4-methylsulfonyl-substituted piperidine urea compounds TNNI3, UMPS, TNNT2 EPHX2 4273/4885TRPV1 2569/4885KMT2A 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.